Fate Therapeutics, Inc. (FATE) is a publicly traded Healthcare sector company. As of May 20, 2026, FATE trades at $1.93 with a market cap of $201.65M and a P/E ratio of -1.69. FATE moved +1.85% today. Year to date, FATE is +91.61%; over the trailing twelve months it is +54.92%. Its 52-week range spans $0.66 to $3.80. Analyst consensus is buy with an average price target of $4.46. Rallies surfaces FATE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FATE financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. FATE recently traded at $1.93. Market cap is $201.65M. P/E ratio is -1.69. Revenue is $6.32M.
| Metric | Value |
|---|---|
| Price | $1.93 |
| Market Cap | $201.65M |
| P/E Ratio | -1.69 |
| EPS | $-1.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.80 |
| 52-Week Low | $0.66 |
| Volume | 1.46M |
| Avg Volume | 0 |
| Revenue (TTM) | $6.32M |
| Net Income | $-129.91M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.65M | $-136.31M | $-1.15 |
| 2024 | $13.63M | $-186.26M | $-1.64 |
| 2023 | $63.53M | $-160.93M | $-1.64 |
| 2022 | $96.30M | $-281.72M | $-2.91 |
7 analysts cover FATE: 0 strong buy, 3 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.46.